Combination of 5-fluorouracil and N1,N11-diethylnorspermine markedly activates spermidine/spermine N1-acetyltransferase expression, depletes polyamines, and synergistically induces apoptosis in colon carcinoma

被引:48
作者
Choi, WY
Gerner, EW
Ramdas, L
Dupart, J
Carew, J
Proctor, L
Huang, P
Zhang, W
Hamilton, SR
机构
[1] Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Unit 85,Div Pathol & Lab Med, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Div Pathol & Lab Med, Houston, TX 77030 USA
[3] Univ Arizona, Arizona Canc Ctr, Dept Biochem & Biophys, Tucson, AZ 85724 USA
关键词
D O I
10.1074/jbc.M409930200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The thymidylate synthase inhibitor 5-fluorouracil (5-FU) is used widely for chemotherapy of colorectal carcinoma. Recent studies showed that 5-FU affects polyamine metabolism in colon carcinoma cells. We therefore examined whether combinations of 5-FU with drugs that specifically target polyamine metabolism, i.e. N-1, N-11-diethylnorspermine (DENSPM) or alpha-difluoromethylornithine (DFMO), have synergistic effects in killing HCT116 colon carcinoma cells with wild-type or absent p53. Our results showed that simultaneous 5-FU and DENSPM, a spermine analogue, synergistically increased transcript levels of the polyamine catabolism enzyme spermidine/spermine N-1-acetyltransferase, depleted spermine and spermidine, increased acetylated spermidine, and produced synergistic tumor cell apoptosis in both p53 wild-type and p53-null variants. By contrast, simultaneous combination of 5-FU with DFMO, an inhibitor of the polyamine biosynthetic enzyme ornithine decarboxylase, depleted putrescine but did not produce synergistic cell killing. Some pre-treatment and post-treatment regimens of DENSPM and DFMO were antagonistic to 5-FU depending on cellular p53 status. Protein and transcriptome expression analysis showed that combined 5-FU and DENSPM treatment activated caspase 9, but not caspase 3, and significantly suppressed NADH dehydrogenases and cytochrome c oxidases, consistent with the observed increase in hydrogen peroxide, loss of mitochondrial membrane potential, and release of cytochrome c. Our findings demonstrate the importance of the polyamine pathway in 5-FU effects and suggest that the combination of 5-FU with DENSPM has potential for development as therapy for colorectal carcinoma.
引用
收藏
页码:3295 / 3304
页数:10
相关论文
共 48 条
[21]   An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug [J].
Ghoshal, K ;
Jacob, ST .
BIOCHEMICAL PHARMACOLOGY, 1997, 53 (11) :1569-1575
[22]   Prospective phase II trial of irinotecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer [J].
Gil-Delgado, MA ;
Guinet, F ;
Castaing, D ;
Adam, R ;
Coeffic, D ;
Durrani, AKS ;
Bismuth, H ;
Khayat, D .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2001, 24 (01) :101-105
[23]   A phase I study of sequential irinotecan and 5-fluorouracil/leucovorin [J].
Goldberg, RM ;
Kaufmann, SH ;
Atherton, P ;
Sloan, JA ;
Adjei, AA ;
Pitot, HC ;
Alberts, SR ;
Rubin, J ;
Miller, LL ;
Erlichman, C .
ANNALS OF ONCOLOGY, 2002, 13 (10) :1674-1680
[24]   The role of polyamine catabolism in polyamine analogue-induced programmed cell death [J].
Ha, HC ;
Woster, PM ;
Yager, JD ;
Casero, RA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (21) :11557-11562
[25]   Differential requirement for Caspase 9 in apoptotic pathways in vivo [J].
Hakem, R ;
Hakem, A ;
Duncan, GS ;
Henderson, JT ;
Woo, M ;
Soengas, MS ;
Elia, A ;
de la Pompa, JL ;
Kagi, D ;
Khoo, W ;
Potter, J ;
Yoshida, R ;
Kaufman, SA ;
Lowe, SW ;
Penninger, JM ;
Mak, TW .
CELL, 1998, 94 (03) :339-352
[26]   THE SEQUENCE OF ELECTRON CARRIERS IN THE REACTION OF CYTOCHROME-C-OXIDASE WITH OXYGEN [J].
HILL, BC .
JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, 1993, 25 (02) :115-120
[27]   Obtaining reliable information from minute amounts of RNA using cDNA microarrays [J].
Hu, LM ;
Wang, J ;
Baggerly, K ;
Wang, H ;
Fuller, GN ;
Hamilton, SR ;
Coombes, KR ;
Zhang, W .
BMC GENOMICS, 2002, 3 (1)
[28]  
Levin VA, 2000, CLIN CANCER RES, V6, P3878
[29]  
Marverti G, 1998, INT J CANCER, V78, P33, DOI 10.1002/(SICI)1097-0215(19980925)78:1<33::AID-IJC7>3.0.CO
[30]  
2-Y